Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9) sciencedirect.com/science/articl… The phase 2 PCS-9 trial evaluated the addition of stereotactic body radiotherapy (SBRT) to standard

✍️ Editorial in European Urology: In the PROBASE trial, 26% of significant prostate cancers in men 45–50 would have been missed with MRI-targeted biopsy alone. 👉 Stabile & Nordström argue systematic biopsy remains essential for young men. 🔗 buff.ly/hnu8YwN

@FOCUS_meeting change de lieu en 2025 : nous vous attendons au Centre de congrès Pierre Baudis à #Toulouse ! 🗓 9 et 10 octobre 2025 💻 Inscriptions/Demande de prise en charge : forms.gle/9sXsYET2fGW386… Jb Beauval Pignot Géraldine Ploussard Guillaume Pouessel Damien Roubaud Guilhem @MRoumiguie Paul Sargos

This is bad news. This is very bad news. The US government has stopped the funding of PubMed, the most comprehensive database of biomedical literature. Why would you do this? This database it literally a matter of life and death.

Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study sciencedirect.com/science/articl… This study evaluated how well Transurethral Resection of Bladder Tumor (TURBT)

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial ejcancer.com/article/S0959-… This post-hoc analysis of the phase III PEACE-1 trial examined the impact of post-progression abiraterone

@FOCUS_meeting it’s tomorrow at the Pierre Baudis Convention Center #Toulouse ! With our presidents Elena Castro et Karim Bensalah🇪🇸🇫🇷 #focus2025meetsSpain #urology #oncology #radiotherapy Jb Beauval Pignot Géraldine Ploussard Guillaume Pouessel Damien Roubaud Guilhem @MRoumiguie Paul Sargos

🚨Just in Nature Medicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 bit.ly/47lt5Oj Prostate Cancer Foundation OncoAlert UroToday.com

Elena Castro Proud and super happy to have you in Toulouse, thanks President 🎉🇪🇸 Ploussard Guillaume Roubaud Guilhem @FOCUS_meeting Morgan Roupret Pr. Alexandre de La Taille Felipe Couñago PhD Constantinos Zamboglou

⚡️ Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study #BladderCancer academic.oup.com/oncolo/advance…

🥁#ESMO25 ABSTRACT RELEASE DAY🥁 #ESMO25 is shaping up to be one of most impactful conferences in recent memory with #PracticeChangingData in Prostate, Bladder and Kidney Cancers! 💫See list of highlighted abstracts 👇

Updated safety and the first efficacy data from the PETRANHA trial (Saruparib (AZD5305), a PARP1-selective inhibitor, plus ARPI) in pts with castration-sensitive mPC (mCSPC) and mCRPC 👉excellent talk by Arun Azad at #ESMO25 OncoAlert UroToday.com PCF Science

De escalated therapy is safe for stage IIA-IIB seminoma! ✅No recurrence since initial presentation in 2021. ✅No severe toxicity. ✅Secondary malignancies only outside of radiotherapy fields. Long term outcomes of SAKK 01/10 by Alexandros Papachristofilou at #ESMO2

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

TiP – EORTC GUCG 2238 De-escalate UroToday.com #ESMO25 🌀n=~1,600 mHSPC: 6-12 mo cont max ADT --> if PSA <0.2, RCT to cont vs intermit max ADT 🌀1 EPs: - Pts not restarting cont max ADT within 1-yr of interrupt - OS using intermit max ADT @ 3-yrs is non-inf to cont max ADT

Congrats to Scott Tagawa on his presentation of PSMA-Addition, and to Arun Azad on a very thoughtful discussion. Compelling data data but agree with Azad’s take that questions remain. Excellent points around the possibility of a “sink effect” & risks of secondary

Retreatment with 177Lu-PSMA in mCRPC pts in the 🇫🇷 EAP UroToday.com #ESMO25 💠n=134 received 2nd sched 💠Retreated pts: ⬆️concomitant ARPI use, but ⬇️ during 2nd sched 💠Med 177Lu-PSMA doses in re-treatment: 3 💠MCC Rx discont: PD (44.6%) 💠Re-treatment: well tolerated

Final analysis of 177Lu-PSMA-617 in an EAP for mCRPC in 🇫🇷 UroToday.com #ESMO25 💠n=3,709, Dec 1/21 - Apr 29/25 💠Concomitant ARPIs: 24.4% 💠mPFS: 7.6 months 💠MCC early Rx disc: PD (46.2%) 💠TRAEs: 12.5%

Elegant talk from Bernard-Tessier at #ESMO25 highlighting novel AR directed therapies. PROTACS, N-terminal domain inh, etc all covered. We met via Laurence Albiges Gustave Roussy on the DFF332 trial for #kidneycancer - excited to hear that she is doing a fellowship at Dana-Farber with

Biomarker analyses from the phase II PT-112 monotherapy study in late-line #mCRPC. Presentation by Roubaud Guilhem. #ESMO25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3KVb3uF ESMO - Eur. Oncology Neeraj Agarwal, MD, FASCO